Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



The Dow's Top 3 Stocks This Week

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

If you'd only read the headlines, you'd think it was a rough week on Wall Street. Employment numbers were terrible and the housing market may be slowing a bit, but stocks moved sideways once again. The Dow Jones Industrial Average (DJINDICES: ^DJI  ) fell just 0.09% this week, and the S&P 500 (SNPINDEX: ^GSPC  ) lost only 1%. Despite the declines overall, there were a few big winners on the Dow this week.

UnitedHealth Group (NYSE: UNH  ) jumped 8.5%, boosted by a surprise increase in Medicare Advantage reimbursements. The government initially proposed a 2.2% cut in rates, but after much lobbying from the industry, it did a 180 and decided to increase reimbursements by 3.3%. Across the board, insurers loved the news, and UnitedHealth won't be under the same margin pressure some had feared in 2014.

AT&T (NYSE: T  ) was second on the Dow, climbing 3.6% for the week. Investors cheered when Facebook announced that the first Facebook Home-specific device, made by HTC, will be exclusive to AT&T. The pop on Thursday was probably overdone, though, because Home will be available on most Android phones and there doesn't appear to be any long-term advantage for AT&T with Home. Friday was also the last day to own AT&T before getting a $0.45-per-share dividend, so that may have boosted the stock slightly late in the week.

Merck (NYSE: MRK  ) rounds out the top three this week, climbing 2.1%. Aside from a lawsuit against India's Glenmark Pharmaceuticals over the potential infringement on two diabetes drugs, it was a fairly quiet week for Merck. The company got a bit of a boost when the Medicare Advantage reimbursement news came out, probably because investors are hoping margins won't be squeezed further down the medical value chain. If insurers are generating less revenue, they'll push for lower prices from pharmaceutical companies, so the higher rates may be an incremental positive for the company. Investors are also looking forward to earnings, which Merck will release on May 1.

Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, the Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more click here to claim your copy today.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2349602, ~/Articles/ArticleHandler.aspx, 9/26/2016 6:48:20 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,094.83 -166.62 -0.91%
S&P 500 2,146.10 -18.59 -0.86%
NASD 5,257.49 -48.26 -0.91%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/26/2016 4:35 PM
^DJI $18094.83 Down -166.62 -0.91%
^GSPC $2146.10 Down -18.59 -0.86%
S&P 500 INDEX CAPS Rating: No stars
MRK $62.15 Down -0.81 -1.29%
Merck and Co. CAPS Rating: ****
T $41.14 Down -0.14 -0.34%
AT and T CAPS Rating: ****
UNH $139.72 Down -0.79 -0.56%
UnitedHealth Group CAPS Rating: ****